The Laboratory AntiPlatelet Efficacy and Clinical Outcome Registry

Completed

• Conditions: Platelet Aggregation Onhibitors
• Interventions: Drug: antiplatelet drugs - P2Y12 antagonists

• Registration Number: NCT02264912
• Lead Sponsor: Faculty Hospital Kralovske Vinohrady

Brief Summary

The ongoing LAPCOR (Laboratory AntiPlatelet efficacy and Clinical Outcome Registry) registry was initiated in 2008 at a tertiary care cardiac center, and consecutive patients, who underwent intracoronary stent implantation, have been included regardless of whether percutaneous coronary intervention (PCI) was performed on urgent or elective basis.Patients were included in the registry after having signed an informed consent for participation. No exclusion criterion has been applied for the registry participation. Efficacy of P2Y12 receptor antagonists has been measured by quantitative flow cytometric analysis of vasodilator-stimulated phosphoprotein (VASP) phosphorylation according to the manufacturer protocol (Platelet VASP; Diagnostica Stago, Biocytex, Asnières, France) on a FACScan flow cytometer (Becton Dickinson). Occurrence of major adverse cardiac events at 30 days, 6-months and one year follow up has been investigated.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-07
• Study First Submitted: 2014-10-09
• Study First Submitted QC: 2014-10-14
• Study First Posted: 2014-10-15
• Primary Completion: 2017-08
• Study Completion: 2018-07
• Status Verified: 2020-07
• Last Update Submitted: 2020-07-20
• Last Update Posted: 2020-07-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2016

Inclusion Criteria

• Patients after stent PCI treated with P2Y12 antagonist
• Written informed consent

Exclusion Criteria

• None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
stent-PCI patients	antiplatelet drugs - P2Y12 antagonists	Consecutive patients, who underwent intracoronary stent implantation, have been included regardless of whether percutaneous coronary intervention (PCI) was performed on urgent or elective basis.

Primary Outcome Measures

Name	Time	Method
laboratory efficacy of antiplatelet drugs measured as residual platelet reactivity, incidence of major adverse cardiovascular events and bleeding complications	During the 12 months after implantation of an intracoronary stent

Trial Locations

Locations (1)

Faculty Hospital Kralovske Vinohrady; 🇨🇿 Prague, Czechia